Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α

Front Immunol. 2024 Feb 27:15:1383704. doi: 10.3389/fimmu.2024.1383704. eCollection 2024.

¹ Division of Gastroenterology, Icahn School of Medicine Mount Sinai, New York, NY, United States.
² St Vincent's Hospital and The University of Melbourne, Melbourne, VIC, Australia.
³ Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
⁴ IRCCS Azienda Ospedaliero-Universitaria di Bologna Italy, Bologna, Italy.
⁵ DIMEC University of Bologna-Italy, Bologna, Italy.
⁶ F. Widjaja Inflammatory Bowel Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
⁷ Research and Development, Prometheus Laboratories, San Diego, CA, United States.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2024.1342477.].

Keywords: clearance; drug response; inflammatory bowel disease; pharmacogenetic; tumor necrosis factor.